Needle-Phobia Fails To Carry The Day: NICE Rejects Orencia For Second-Line Rheumatoid Arthritis
This article was originally published in The Pink Sheet Daily
U.K.'s cost watchdog, the National Institute for Health and Clinical Excellence, has rejected Bristol's Orencia as a second-line therapy for rheumatoid arthritis in draft guidance, although it has changed its mind on use of the drug before.
You may also be interested in...
In a day of three positive recommendations helped by discounts, Bristol’s Orencia for rheumatoid arthritis, Novartis’ Xolair for Asthma and InterMune’s Esbriet for IPF finally make it onto the U.K.’s NHS payroll.
U.K. spending watchdog recommends Multaq for atrial fibrillation and biologic therapies for rheumatoid arthritis and psoriatic arthritis, but rejects imatinib for adjuvant therapy of gastrointestinal stromal tumors.
Bristol will file an appeal to the decision within 10 working days, the firm tells “The Pink Sheet” DAILY.